Select Your Region
Americas
Europe
Africa
Global
Profile settings
Update your username and manage your account
Search results
Review the results we have found for you.
Use the filters to narrow down the results list and easily find the study you look for.
Refine your search
Search
Non Hodgkin Lymphoma (NHL)
Location
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
We found 58 results for 'NON HODGKIN LYMPHOMA (NHL)'Use the filters to narrow down your search.
1 
Study StatusRecruiting1 A Study Evaluating the Effects of the Body on and the Safety and Effectiveness of Mosunetuzumab in Patients with Relapsed or Refractory Follicular Lymphoma.
An Open-label, Multicenter, Phase I Trial Evaluating the Pharmacokinetics, Safety and Efficacy of Mosunetuzumab as a Single-agent in Patients with Relapsed or Refractory Follicular Lymphoma
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Follicular Lymphoma
- YO43555
2 Study StatusRecruiting2 A study to evaluate the safety, tolerability, processing by the body, mechanism of action, and effectiveness of glofitamab following obinutuzumab pretreatment in patients with B-cell non-Hodgkin lymphoma
A Phase Ib, open-label, dose-escalation, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of subcutaneous glofitamab following obinutuzumab pretreatment in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
- Cancer,
- Non Hodgkin Lymphoma (NHL)
- BP43015
3 Study StatusRecruiting3 A clinical trial to test CC-220 or CC-99282 in combination with mosunetuzumab, and CC-99282 in combination with glofitamab, in people with B-cell non-Hodgkin lymphoma.
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- Cancer,
- Non Hodgkin Lymphoma (NHL)
- NCT05169515, CO43805, 2023-505185-28-00
4 Study StatusRecruiting4 A clinical trial to look at the safety and effectiveness of mosunetuzumab plus lenalidomide for treating follicular lymphoma
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Follicular Lymphoma
- NCT04246086, CO41942, 2023-507236-20-00
5 Study StatusRecruiting5 A clinical trial to look at how well glofitamab works on its own, and in combination with standard cancer chemotherapy plus immunotherapy in children and young adults with B-cell non-Hodgkin lymphoma (B-NHL) after one or multiple standard therapies have not worked
A Study to Evaluate Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Mature B-Cell Non-Hodgkin Lymphoma,
- Mature B-Cell Lymphoma
- NCT05533775, CO43810
6 Study StatusRecruiting6 A clinical trial to compare how well glofitamab on its own works versus standard treatment in people with mantle cell lymphoma that has come back after or has not responded to treatment
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Lymphoma
- NCT06084936, GO43878, 2023-503206-37-00
7 Study StatusRecruiting7 A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Lymphoma
- NCT06624085, GO44900
8 Study StatusRecruiting8 A clinical trial to look at whether RO7227166 combined with another treatment (either obinutuzumab or glofitamab) is safe and effective at different doses for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Lymphoma
- NCT04077723, BP41072, 2019-000416-28,2022-502616-37-00
9 Study StatusRecruiting9 A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT05954910, ML44616
10 Study StatusRecruiting10 A clinical trial to compare glofitamab plus Pola-R-CHP with Pola-R-CHP alone in people with untreated large B-cell lymphoma
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
- Cancer,
- Non Hodgkin Lymphoma (NHL),
- Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT06047080, GO44145